The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers

An open-label, placebo-controlled, randomized, two-way crossover study was performed in 12 healthy volunteers (between 20 and 44 years of age) to assess the effect of orlistat, a gastrointestinal lipase inhibitor that reduces dietary fat absorption and is being developed for weight control in obesity, on the absorption of vitamins A and E. Each participant received a single oral dose of 25,000 IU vitamin A followed 24 hours later by a single oral dose of 400 IU vitamin E on two separate occasions: during oral administration of 120 mg orlistat or placebo three times daily for 9 days. The two treatments were separated by a washout period of at least 2 weeks. Serial blood samples for pharmacokinetic analysis were collected at specified times over 24 hours after each dose of vitamin A for determination of serum concentrations of retinol, and over a period of 5 days after each dose of vitamin E for determination of serum concentrations of alpha-tocopherol, total cholesterol, and triglycerides. Orlistat significantly reduced the absorption of vitamin E (approximately 43% according to maximum concentration and approximately 60% according to area under the concentration-time curve), but not that of vitamin A, at the dose levels studied. The results of this study will aid in the implementation of a vitamin supplementation strategy, should vitamin deficiency occur in patients undergoing orlistat therapy.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				E. Idelevich, W. Kirch, and C. Schindler Current pharmacotherapeutic concepts for the treatment of obesity in adults Therapeutic Advances in Cardiovascular Disease, February 1, 2009; 3(1): 75 - 90. [Abstract] [PDF]

				C. S. Elangbam REVIEW PAPER: Current Strategies in the Development of Anti-obesity Drugs and Their Safety Concerns Vet. Pathol., January 1, 2009; 46(1): 10 - 24. [Abstract] [Full Text] [PDF]

				K. C. Dunican, A. R. Desilets, and R. J. DeBellis State of the Art Review: Long-term Pharmacotherapy for Overweight and Obesity: A Review of Sibutramine, Orlistat, and Rimonabant American Journal of Lifestyle Medicine, October 1, 2007; 1(5): 367 - 388. [Abstract] [PDF]

				J. Zhi, R. Moore, L. Kanitra, and T. E. Mulligan Effects of Orlistat, a Lipase Inhibitor, on the Pharmacokinetics of Three Highly Lipophilic Drugs (Amiodarone, Fluoxetine, and Simvastatin) in Healthy Volunteers J. Clin. Pharmacol., April 1, 2003; 43(4): 428 - 435. [Abstract] [Full Text] [PDF]

				L. D. M. C.-B. Ferreira, P. U. Huey, B. E. Pulford, D. N. Ishii, and R. H. Eckel Sciatic Nerve Lipoprotein Lipase Is Reduced in Streptozotocin-Induced Diabetes and Corrected by Insulin Endocrinology, April 1, 2002; 143(4): 1213 - 1217. [Abstract] [Full Text] [PDF]

				L.-N. Chan Redefining Drug-Nutrient Interactions Nutr Clin Pract, October 1, 2000; 15(5): 249 - 252. [Abstract] [PDF]

				J. Hauptman, C. Lucas, M. N. Boldrin, H. Collins, and K. R. Segal Orlistat in the Long-term Treatment of Obesity in Primary Care Settings Arch Fam Med, February 1, 2000; 9(2): 160 - 167. [Abstract] [Full Text] [PDF]

				D. A. Anderson and T. A. Wadden Treating the Obese Patient: Suggestions for Primary Care Practice Arch Fam Med, March 1, 1999; 8(2): 156 - 167. [Abstract] [Full Text] [PDF]